期刊文献+

依达拉奉滴丸体外溶出度测定

Determination of Dissolution Rate of Edaravone Dropping Pills
下载PDF
导出
摘要 目的建立测定依达拉奉滴丸中依达拉奉溶出度的方法。方法选用小杯法,以0.1mol·L^-1盐酸为溶出介质,转速为50r·min^-1,用高效液相色谱法测定依达拉奉的溶出度,绘制溶出曲线,计算溶出参数T50、Td、m,并用相似因子法进行评价。结果依达拉奉的检测浓度在0.1000~1.000mg·mL^-1(r=0.9996)范围内与其峰面积积分值呈良好的线性关系;依达拉奉的平均回收率为98.23%(RSD=2.17%),3批样品溶出度相似。结论本方法简便、准确、可靠,可用于测定依达拉奉滴丸中主要组分的溶出度。 Objective To determine the dissolution rates of Edaravone in Edaravone dropping pills simultaneously. Methods The small glass cup method was adopted in which 0.1 mol·L^-1 hydrochloric acid was taken as solvent with a rotating speed of 50 r·min^-1. The dissolution rates of Edaravone were determined by HPLC. The dissolution curves were drawn, and the dissolution parameters including T50, Td, and were computed and evaluated using similar factors method. Results The Edaravone were linear over the range of 0.1000~ 1.0000mg·mL^-1 (r=0.9996). The average recoveries of the ingredients were 98.23 % (RSD=2.17 %). The three batches samples were proved to be of similar dissolution rates. Conclusion The determination method is simple, accurate and reliable, which can be applied to determine the dissolution rates of Edaravone in Edaravone dropping pills simultaneously.
出处 《疾病监测与控制》 2014年第6期366-367,365,共3页 Journal of Diseases Monitor and Control
关键词 依达拉奉 滴丸 溶出度 高效液相色谱法 Edaravone Dropping pills Dissolution HPLC
  • 相关文献

参考文献4

  • 1Yukihito Higashi, Daisuke Jitsuiki. Kazuaki Chayama and Masao Yoshizumi. Edaravone(3-Methyl-1-Phenyl-2-Pyrazolin-5-one). A Novel Free Radical Scavenger. for Treatment of Cardiovascular Diseases[S]. Recent Patents on Cardiovascular Drug Discovery, 2006,1,85-93.
  • 2杨政,吴玉林.治疗急性脑梗死的新型脑保护药依达拉奉[J].中国新药杂志,2002,11(12):911-913. 被引量:353
  • 3Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent[J]. Nippon Yakurigaku Zasshi, 2002,118(5):301.
  • 4Center for drug evaluation and research, FDh. Guidance for industry bioavailability and bieequivalences studies for orally administered drug products: general considerations [EB/OL].http://www. fda. gov/cder/guidance/5356fnl, pdf. 2004 11:25.

二级参考文献11

  • 1横田慎一 熊毅雄治 内海光朝.A Pharmacokinetic Study of MCI—186,a novel drug for cerebrovascular disease in elderly and young healthy subjects[J].临床药理,1997,28(3):693-702.
  • 2Mizuno A,Umemura K,Nakashima M.Inhibitory effect MCI-186,a free radical scavenger,on cerebral ischemia following rat middle cerebral artery occlusion[J].Gen Pharmacol,1998,30(4)∶575-578.
  • 3Kawai H,Nakai H,Misao S,et al.Effects of a novel free radical scavenger,MCI-186,on ischemic brain damage in the rat distal middle cerebral artery occlusion model[J].J Pharmacol Exp Ther,1997,281(2)∶921-927.
  • 4Tabrizchi R.Edaravone Mitsubishi-Tokyo[J].Curr Opin Investig Drugs,2000,1(3)∶347-454.
  • 5Yamamoto T,Yuki S,Watanabe T,et al.Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia[J].Brain Res,1997,762(12)∶240-242.
  • 6Watanabe T,Egawa M.Effects of an antistroke agent MCI-186 on cerebral arachidonate cascades[J].J Pharmacol Exp Ther,1994,271(3)∶1624-1629.
  • 7Watanabe T,Morita I,Nishi H,et al.Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro[J].Prostaglandins Leukotrienes Essent Fatty Acids,1998,33(1)∶81-87.
  • 8Mitsumori K,Sakuragi M,Kitami K,et al.The effect MCI-186 on regional cerebral blood flow in patients with acute cerebral infarction-A sequential SPECT study[J].Ther Res,1998,19(4)∶1333-1345.
  • 9山本美奈子 高松康雄.Pharmacokinetic studies of 3—methyl—1—phenyl—2—pyrazolin—5—one(MCI—186):protein binding and distribution to red blood cell[J].药理と治疗,1997,25(17):1755-1763.
  • 10大友英一 东仪英夫 小暮久也.MCI—186の脑梗死急性期に对する效果[J].Ther Res,1998,19(4):1311-1332.

共引文献352

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部